Clinical Research Directory
Browse clinical research sites, groups, and studies.
Theophylline Treatment for Pseudohypoparathyroidism
Sponsor: Vanderbilt University Medical Center
Summary
Pseudohypoparathyroidism is a genetic disorder with limited treatment options. Patients have early-onset obesity, short stature and increased risk of type 2 diabetes. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. The investigators hypothesize that theophylline will cause weight loss, improve glucose tolerance and slow growth plate closure in children and young adults.
Official title: Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism
Key Details
Gender
All
Age Range
13 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
29
Start Date
2018-09-01
Completion Date
2026-12-01
Last Updated
2026-02-20
Healthy Volunteers
No
Interventions
Theophylline
oral theophylline
Placebos
oral placebo
Locations (1)
Ashley Shoemaker
Nashville, Tennessee, United States